Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.

G L Uy; L J Costa; P N Hari; M J Zhang; J X Huang; K C Anderson; C N Bredeson; N S Callander; R F Cornell; M A D Perez; A Dispenzieri; C O Freytes; R P Gale; A Garfall; M A Gertz; J Gibson; M Hamadani; H M Lazarus; M E Kalaycio; R T Kamble; M A Kharfan-Dabaja; A Y Krishnan; S K Kumar; R A Kyle; H J Landau; C H Lee; A Maiolino; D I Marks; T M Mark; R Munker; T Nishihori; R F Olsson; M Ramanathan; T E Rodriguez; A A Saad; B N Savani; G J Schiller; H C Schouten; J R Schriber; E Scott; S Seo; M Sharma; S Ganguly; E A Stadtmauer; J Tay; L B To; D H Vesole; D T Vogl; J L Wagner; B Wirk; W A Wood; A D'Souza

doi:10.1038/bmt.2015.190

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.

G L Uy, L J Costa, P N Hari, M J Zhang, J X Huang, K C Anderson, C N Bredeson, N S Callander, R F Cornell, M A D Perez, A Dispenzieri, C O Freytes, R P Gale, A Garfall, M A Gertz, J Gibson, M Hamadani, H M Lazarus, M E Kalaycio, R T KambleM A Kharfan-Dabaja, A Y Krishnan, S K Kumar, R A Kyle, H J Landau, C H Lee, A Maiolino, D I Marks, T M Mark, R Munker, T Nishihori, R F Olsson, M Ramanathan, T E Rodriguez, A A Saad, B N Savani, G J Schiller, H C Schouten, J R Schriber, E Scott, S Seo, M Sharma, S Ganguly, E A Stadtmauer, J Tay, L B To, D H Vesole, D T Vogl, J L Wagner, B Wirk, W A Wood, A D'Souza^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (⩾0.5 × 10(9)/L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (⩾20 × 10(9)/L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.

Original language	English
Pages (from-to)	1513
Number of pages	1
Journal	Bone Marrow Transplantation
Volume	50
Issue number	12
DOIs	https://doi.org/10.1038/bmt.2015.190
Publication status	Published - 2015

Access to Document

10.1038/bmt.2015.190

Cite this

Uy, G. L., Costa, L. J., Hari, P. N., Zhang, M. J., Huang, J. X., Anderson, K. C., Bredeson, C. N., Callander, N. S., Cornell, R. F., Perez, M. A. D., Dispenzieri, A., Freytes, C. O., Gale, R. P., Garfall, A., Gertz, M. A., Gibson, J., Hamadani, M., Lazarus, H. M., Kalaycio, M. E., ... D'Souza, A. (2015). Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplantation, 50(12), 1513. https://doi.org/10.1038/bmt.2015.190

@article{288fa66ce67f4e57b5abfae4551404da,

title = "Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.",

abstract = "In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (⩾0.5 × 10(9)/L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (⩾20 × 10(9)/L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.",

author = "Uy, {G L} and Costa, {L J} and Hari, {P N} and Zhang, {M J} and Huang, {J X} and Anderson, {K C} and Bredeson, {C N} and Callander, {N S} and Cornell, {R F} and Perez, {M A D} and A Dispenzieri and Freytes, {C O} and Gale, {R P} and A Garfall and Gertz, {M A} and J Gibson and M Hamadani and Lazarus, {H M} and Kalaycio, {M E} and Kamble, {R T} and Kharfan-Dabaja, {M A} and Krishnan, {A Y} and Kumar, {S K} and Kyle, {R A} and Landau, {H J} and Lee, {C H} and A Maiolino and Marks, {D I} and Mark, {T M} and R Munker and T Nishihori and Olsson, {R F} and M Ramanathan and Rodriguez, {T E} and Saad, {A A} and Savani, {B N} and Schiller, {G J} and Schouten, {H C} and Schriber, {J R} and E Scott and S Seo and M Sharma and S Ganguly and Stadtmauer, {E A} and J Tay and To, {L B} and Vesole, {D H} and Vogl, {D T} and Wagner, {J L} and B Wirk and Wood, {W A} and A D'Souza",

year = "2015",

doi = "10.1038/bmt.2015.190",

language = "English",

volume = "50",

pages = "1513",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "12",

}

Uy, GL, Costa, LJ, Hari, PN, Zhang, MJ, Huang, JX, Anderson, KC, Bredeson, CN, Callander, NS, Cornell, RF, Perez, MAD, Dispenzieri, A, Freytes, CO, Gale, RP, Garfall, A, Gertz, MA, Gibson, J, Hamadani, M, Lazarus, HM, Kalaycio, ME, Kamble, RT, Kharfan-Dabaja, MA, Krishnan, AY, Kumar, SK, Kyle, RA, Landau, HJ, Lee, CH, Maiolino, A, Marks, DI, Mark, TM, Munker, R, Nishihori, T, Olsson, RF, Ramanathan, M, Rodriguez, TE, Saad, AA, Savani, BN, Schiller, GJ, Schouten, HC, Schriber, JR, Scott, E, Seo, S, Sharma, M, Ganguly, S, Stadtmauer, EA, Tay, J, To, LB, Vesole, DH, Vogl, DT, Wagner, JL, Wirk, B, Wood, WA & D'Souza, A 2015, 'Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.', Bone Marrow Transplantation, vol. 50, no. 12, pp. 1513. https://doi.org/10.1038/bmt.2015.190

TY - JOUR

T1 - Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.

AU - Uy, G L

AU - Costa, L J

AU - Hari, P N

AU - Zhang, M J

AU - Huang, J X

AU - Anderson, K C

AU - Bredeson, C N

AU - Callander, N S

AU - Cornell, R F

AU - Perez, M A D

AU - Dispenzieri, A

AU - Freytes, C O

AU - Gale, R P

AU - Garfall, A

AU - Gertz, M A

AU - Gibson, J

AU - Hamadani, M

AU - Lazarus, H M

AU - Kalaycio, M E

AU - Kamble, R T

AU - Kharfan-Dabaja, M A

AU - Krishnan, A Y

AU - Kumar, S K

AU - Kyle, R A

AU - Landau, H J

AU - Lee, C H

AU - Maiolino, A

AU - Marks, D I

AU - Mark, T M

AU - Munker, R

AU - Nishihori, T

AU - Olsson, R F

AU - Ramanathan, M

AU - Rodriguez, T E

AU - Saad, A A

AU - Savani, B N

AU - Schiller, G J

AU - Schouten, H C

AU - Schriber, J R

AU - Scott, E

AU - Seo, S

AU - Sharma, M

AU - Ganguly, S

AU - Stadtmauer, E A

AU - Tay, J

AU - To, L B

AU - Vesole, D H

AU - Vogl, D T

AU - Wagner, J L

AU - Wirk, B

AU - Wood, W A

AU - D'Souza, A

PY - 2015

Y1 - 2015

N2 - In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (⩾0.5 × 10(9)/L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (⩾20 × 10(9)/L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.

AB - In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (⩾0.5 × 10(9)/L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (⩾20 × 10(9)/L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.

U2 - 10.1038/bmt.2015.190

DO - 10.1038/bmt.2015.190

M3 - Article

C2 - 26301967

SN - 0268-3369

VL - 50

SP - 1513

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 12

ER -